S100A2 and breast carcinoma: S100A2 is expressed in 37% of specimens of carcinoma in situ, and in <15% of breast cancer samples in vivo [63], suggesting that the loss of S100A2 is related to the development of breast cancer and does not appear to be with an early phase of tumor development.